Gland Pharma’s Board of Directors has approved the acquisition of 100% of the equity share capital of Gland Pharma USA Inc. from Gland Pharma International Pte. Ltd., a wholly owned subsidiary of the company. 

The transaction will make Gland Pharma USA a direct wholly owned subsidiary of Gland Pharma. 

The acquisition, approved at the Board meeting held on September 13, 2026, is intended to streamline Gland Pharma’s corporate structure by removing multiple layers of ownership. 

As per the company, the transaction is not expected to have any material impact on its business or operations. 

The transaction is classified as a related-party transaction and will be undertaken on an arm’s-length basis, with the consideration determined by an independent valuer. 

The company will acquire the shares for a cash consideration of US$ 501,208, representing 100% ownership of Gland Pharma USA. 

Gland Pharma USA, incorporated on March 7, 2022, operates in the pharmaceutical industry, with its principal activity being the marketing and distribution of pharmaceutical products in the United States. 

The entity had reported turnover of US$ 483,808 in FY24, USD 87,342 in FY25 and nil turnover in FY26. 

Gland Pharma expects to complete the acquisition by October 31, 2026.